R&D

For yeasts and bacteria, LHS centers of excellence

For over 80 years, the company has continuously dedicated its efforts to innovation, either in the fundamental and clinical research of probiotics, or protective and formulation technologies to deliver high-quality, state of the art probiotics in response to very dynamic market needs.

DSC_3318b light2

Lallemand Health Solutions operates two principal research facilities. The unit in Toulouse (France) specializes in the development of new processes and technologies. Our R&D departement is optimizing probiotics production processes for bacteria and yeasts, improving strains viability, galenic forms, packaging… in order to constantly offer high-quality standards for strains, blends or custom-made formulations.

 For its part, the laboratory in Montreal (Canada) is dedicated to the characterization of strains and host response. The lab is located within the National research council of Montreal (NRC) and is Biosecurity Level 2-certified, thus authorizing the company’s expert team of eight researchers to study the impact of probiotics on the effects of pathogens. One of their major research concern is the genomic and proteomic on microorganisms.

Innovation through partnerships

_DSC3149
Dr V. Pichette, from Maisonneuve Rosemont Hospital

New exciting research henceforth focuses on the scientific and clinical documentation of probiotic formulations designed specifically for their health benefits. Dedicated to continuously improving scientific performance, Lallemand Health Solutions has forged numerous collaborative relationships with public and private partners, which include Canadian universities (McGill University, Université de Montréal, Université Laval), pharmaceutical laboratories and world-renowned research centers located primarily in North America and Europe. The fundamental purpose of these affiliations is to bring the best expertise to its strains and finished products in the areas of strain grading, pharmacological and action mode analysis, toxicological assessment, pre-clinical and clinical trials and pharmacokinetics.

For instance, our partnership with the Maisonneuve Rosemont Hospital and Dr Vincent Pichette, who heads up the nephro-pharmacology research center and his team, began with Harmonium back in 2009. The collaboration and development focused primarily on the required tools and methodologies to properly identify and characterize the diverse probiotic strains in the Harmonium collection. This systematic characterization produced a more detailed understanding of the potential health benefits and applications possible. This extensive research has already been presented at two international conferences, and is in the process of being published.